STOCK TITAN

Camurus Sweden - CAMRF STOCK NEWS

Welcome to our dedicated page for Camurus Sweden news (Ticker: CAMRF), a resource for investors and traders seeking the latest updates and insights on Camurus Sweden stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Camurus Sweden's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Camurus Sweden's position in the market.

Rhea-AI Summary

Camurus AB (NASDAQ: CAMX) announced on May 3, 2021, that the Australian TGA has approved significant label updates for its Buvidal® Weekly and Buvidal® Monthly injections. Key changes include a new 160 mg dose for Buvidal Monthly, allowing direct initiation onto Buvidal Weekly without prior sublingual treatment, and revised contraindications regarding pregnancy and lactation. This approval aligns with European labeling and aims to enhance treatment options for opioid dependence. In 2020, over 53,000 Australians received opioid dependence treatment, marking a 4.7% annual increase attributed to long-acting injectable treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Camurus, based in Lund, Sweden, announced a positive opinion from the CHMP of the EMA for the marketing authorization of a new 160mg monthly dose of Buvidal (buprenorphine) for treating opioid dependence in patients aged 16 and older. This opinion signifies a significant advancement in treatment options within Europe, offering individualized dosing strategies. Buvidal, already a groundbreaking long-acting injectable treatment, has shown superior patient outcomes compared to daily sublingual alternatives. The final marketing authorization is expected from the European Commission by the end of May 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Camurus Sweden (CAMRF)?

The current stock price of Camurus Sweden (CAMRF) is $59.975 as of February 24, 2025.

What is the market cap of Camurus Sweden (CAMRF)?

The market cap of Camurus Sweden (CAMRF) is approximately 2.7B.
Camurus Sweden

OTC:CAMRF

CAMRF Rankings

CAMRF Stock Data

2.74B
35.13M
46.12%
23.56%
Biotechnology
Healthcare
Link
Sweden
Lund